Supportive Care in Myelofibrosis

Opinion
Video

A hematology specialist provides clinical insights on supportive care practices for patients with myelofibrosis.

Recent Videos
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Related Content
We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

American Society for Transplantation and Cellular Therapy
September 3rd 2025
Article

Researchers from the BMT CTN reported that posttransplant cyclophosphamide-based GVHD prophylaxis significantly improves outcomes for adults aged 70 years and older undergoing allo-HCT.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Exa-cel Exhibits Meaningful HRQoL Benefit in Severe Sickle Cell Disease

Roman Fabbricatore
August 31st 2025
Article

The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Ariana Pelosci
August 25th 2025
Article

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.